Search Press releases Keywords From To 9 Nov 2026 ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure Read More 9 Nov 2026 BE BOLD: BIMZELX[®] (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI[®] (risankizumab) at Week 16, with clinical improvements sustained through Week 24 Read More 4 Nov 2026 UCB advances its digital antibody engineering program with new Cradle collaboration Read More 22 Oct 2026 Strong Performance Drives Further Upgrade to UCB’s 2026 Financial Guidance Read More 19 Oct 2026 Transparency notification Wellington Read More 16 Oct 2026 UCB announces U.S. FDA approval for ZILBRYSQ[®] (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 67 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe